SAN DIEGO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV - News) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs. The patent application is based upon clinical investigations conducted by MediciNova researchers which showed an apparent disease-modifying benefit in which brain volume loss, or brain atrophy, commonly associated with disease progression, was reduced by oral administration of ibudilast to a group of multiple sclerosis patients including some subjects with progressive multiple sclerosis, in a dose-related fashion over at least a 10-month treatment period.
Multiple sclerosis (MS) is recognized as a chronic disease in which disability progresses over time. Patients suffering from progressive forms of MS tend to have a poor prognosis and have greater levels of disability. Robert J. Fox, M.D., M.S., FAAN, Medical Director of Mellen Center for MS, Cleveland Clinic, noted that, "Despite recent improvements in pharmacotherapy for relapsing remitting multiple sclerosis, treatment options in progressive multiple sclerosis are extremely limited in the absence of relapses. There is great need for safe, effective, and conveniently-administered therapies for progressive MS."
Obtaining long-term protection of market exclusivity for the use of ibudilast in certain neurological conditions has been a key component of MediciNova's development strategy for the MN-166 program. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, noted that, "We are very pleased to receive notice of this patent allowance for ibudilast in progressive MS. Moreover, we anticipate that this allowance will facilitate further development and business options around this program."
About Ibudilast
Ibudilast has been used in asthma and post-stroke disorders in Japan for around 20 years. MediciNova has demonstrated the potential utility of ibudilast in the treatment of neurological disorders at higher doses with encouraging outcomes in company-sponsored clinical trials in multiple sclerosis (MS) and neuropathic pain. MediciNova's collaborative trial planning with drug addiction investigators at organizations like Columbia/NYSPI and UCLA has led to National Institute on Drug Abuse (NIDA)-to support clinical investigations of the use of ibudilast to treat both opioid and methamphetamine addiction. A Phase 2 investigator-sponsored trial of ibudilast in the treatment of chronic medication overuse headache (MOH) pain is also ongoing in Australia. MediciNova's priorities include pursuing Phase 2 proof-of-concept trials of ibudilast for the treatment of progressive MS and/or neuropathic pain through non-dilutive funding.
About MediciNova
MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a commercial focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential, and patent coverage of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166/AV411). Each drug candidate is involved in clinical trials under U.S. and Investigator INDs. MediciNova is engaged in strategic partnering discussions to support further development of the MN-221 and ibudilast programs. Additionally, MediciNova will seek to monetize opportunistically its other pipeline candidates. For more information on MediciNova, Inc., please visit http://www.medicinova.com.
The MediciNova, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3135
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our the potential utility of ibudilast in the treatment of progressive MS and other neurological disorders and the proposed proof of concept trial of ibudilast, including any implication that the company will have the ability to execute on its priorities. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements, include, but are not limited to, the risk and certainties of raising additional capital to fund clinical development of Ibidulast, risks and uncertainties inherent in clinical trials, product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities, the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete prod
uct development plans and MediciNova's ability to raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2010 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
Follow this link:
MediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis
- Who? Why? How? - Searching for the Cause of Multiple Sclerosis Part 1 -- National MS Society [Last Updated On: August 17th, 2024] [Originally Added On: May 9th, 2011]
- Multiple Sclerosis - SABOTEUR [Last Updated On: August 17th, 2024] [Originally Added On: May 23rd, 2011]
- multiple sclerosis fail [Last Updated On: August 17th, 2024] [Originally Added On: June 8th, 2011]
- Multiple Sclerosis Walk [Last Updated On: August 17th, 2024] [Originally Added On: June 10th, 2011]
- Multiple Sclerosis - Faces of MS [Last Updated On: August 17th, 2024] [Originally Added On: June 10th, 2011]
- Tricia's Story of Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Tricia's Story of Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: June 19th, 2011]
- Living with MS - Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: June 22nd, 2011]
- Living with Multiple Sclerosis - Having a Social Life [Last Updated On: August 17th, 2024] [Originally Added On: June 30th, 2011]
- Multiple Sclerosis: ms relapse [Last Updated On: August 17th, 2024] [Originally Added On: July 5th, 2011]
- Multiple Sclerosis - The Nebraska Medical Center [Last Updated On: August 17th, 2024] [Originally Added On: July 18th, 2011]
- Living With Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: July 29th, 2011]
- Life After MS (Multiple Sclerosis) [Last Updated On: August 17th, 2024] [Originally Added On: August 11th, 2011]
- CCTV#16: Multiple Sclerosis and Cannabis Use [Last Updated On: August 17th, 2024] [Originally Added On: September 26th, 2011]
- Ogg's Blog Episode 1 - Life with Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: October 6th, 2011]
- Ogg's Blog Episode 1 - Life with Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: October 6th, 2011]
- [Symptoms of Multiple Sclerosis] - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Multiple Sclerosis - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 18th, 2011]
- Living with Multiple Sclerosis - MS and Genetics - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 10th, 2011]
- Open Door: MS - Part 1 - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Multiple Sclerosis - Myelin Repair - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 30th, 2011]
- Breakthrough Multiple Sclerosis Treatment? - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 18th, 2011]
- The Alternative - MultipleSclerosis (MS) - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 24th, 2011]
- Multiple Sclerosis Goggles - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 28th, 2011]
- Multiple Sclerosis Treatment - Mayo Clinic - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 5th, 2012]
- Multiple sclerosis (MS) - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Multiple Sclerosis - Kimberley's Story - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Multiple Sclerosis - Kimberley's Story - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Images of MS... - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 25th, 2012]
- Sanofi faces uphill struggle in MS drug market [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple ... [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- My life with multiple sclerosis! - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Financial Well-Being Series: Invest in Yourself - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Judy's MS Story - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Judy's MS Story - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- CCSVI - Multiple Sclerosis and the Immune System - David Hubbard MD - CCSVI - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Spasticity and MS: Management Strategies - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Past 3 Months of MS - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- MS, Vitamin D and Viruses...a MUST SEE! - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- P4A 2011 : Multiple Sclerosis - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- TEDxIowaCity - Dr. Terry Wahls - Minding Your Mitochondria - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Aging and MS -- National MS Society - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- New Study Tests Possible Treatment for MS - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Matts MS: Living With Multiple Sclerosis - Where Have I Been? - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- MS Fatigue - Multiple Sclerosis - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 6th, 2012]
- Multiple Sclerosis: Knowing Me, Stalking You (Year 2, Episode 7 - jrmcg1) - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Multiple Sclerosis: A baby! - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Multiple Sclerosis: vLogging for Shift.ms and a Lumbar Puncture! (Year 2, Episode 5 - jrmcg1) - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Personal Insights and Tools for Coping with MS - Support Systems - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- So Signs Of Multiple Sclerosis Under Stress 12012011 - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Multiple Sclerosis- A love story - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- MS: The Basics - What is Multiple Sclerosis? - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Multiple Sclerosis, Stem Cells, and Hope, Part 2 - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 9th, 2012]
- Dr Roe talks about MS.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- Managing MS Symptoms: Dizziness - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Progressive MS: The People's Hot Topic - part one - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Progressive MS: The People's Hot Topic - part one - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- The Treatment and Management of MS Exacerbations - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- MS Biology Project - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- How multiple sclerosis killed me and LOVE brought me back to life.. - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Repair MS ~ Jan. 2012 Update ~ Montel Williams - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Hope for multiple sclerosis victims [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- RAMS preliminaries successful [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Saskatchewan starts to fill trial spots for controversial MS liberation therapy [Last Updated On: August 17th, 2024] [Originally Added On: February 26th, 2012]
- MS and Antibiotics (Diary Parte 1) - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 26th, 2012]
- Multiple sclerosis: Damaged myelin not the trigger, study finds [Last Updated On: August 17th, 2024] [Originally Added On: February 28th, 2012]
- Multiple sclerosis: Damaged myelin not the trigger [Last Updated On: August 17th, 2024] [Originally Added On: February 28th, 2012]
- Multiple sclerosis walk attracts 700 [Last Updated On: August 17th, 2024] [Originally Added On: February 28th, 2012]
- Opexa Therapeutics Reports Year End 2011 Financial Results and Provides Corporate Update [Last Updated On: August 17th, 2024] [Originally Added On: February 28th, 2012]
- Leann Reynolds: Multiple Sclerosis and Caregiving [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Multiple sclerosis won't slow down Hilton Head woman [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Multiple sclerosis won't slow down Hilton Head woman [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Jeff Simpson has Multiple Sclerosis - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- March is Multiple Sclerosis Awareness Month [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Gazette.Net: National Multiple Sclerosis Society names Frederick Walk MS Ambassador [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- From monkeys to medication: New research into helping people with MS [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Multiple Sclerosis (MS) - Before and after the CCSVI procedure - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Pregnancy seems to protect against multiple sclerosis [Last Updated On: August 17th, 2024] [Originally Added On: March 9th, 2012]